Last reviewed · How we verify

BPZE1 pertussis vaccine and Boostrix

ILiAD Biotechnologies · Phase 2 active Biologic

BPZE1 pertussis vaccine and Boostrix is a vaccine Biologic drug developed by ILiAD Biotechnologies. It is currently in Phase 2 development for Pertussis (whooping cough) prevention in adolescents and adults.

BPZE1 is a live attenuated pertussis vaccine designed to induce mucosal and systemic immunity against Bordetella pertussis, while Boostrix is a combined acellular pertussis booster vaccine.

BPZE1 is a live attenuated pertussis vaccine designed to induce mucosal and systemic immunity against Bordetella pertussis, while Boostrix is a combined acellular pertussis booster vaccine. Used for Pertussis (whooping cough) prevention in adolescents and adults.

At a glance

Generic nameBPZE1 pertussis vaccine and Boostrix
SponsorILiAD Biotechnologies
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 2

Mechanism of action

BPZE1 is a genetically modified live vaccine strain that replicates in the respiratory mucosa to stimulate both cellular and humoral immune responses at the site of infection. Boostrix is an acellular pertussis vaccine containing inactivated toxins and surface antigens that provides booster immunity. The combination approach aims to enhance protective immunity against pertussis through complementary mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about BPZE1 pertussis vaccine and Boostrix

What is BPZE1 pertussis vaccine and Boostrix?

BPZE1 pertussis vaccine and Boostrix is a vaccine drug developed by ILiAD Biotechnologies, indicated for Pertussis (whooping cough) prevention in adolescents and adults.

How does BPZE1 pertussis vaccine and Boostrix work?

BPZE1 is a live attenuated pertussis vaccine designed to induce mucosal and systemic immunity against Bordetella pertussis, while Boostrix is a combined acellular pertussis booster vaccine.

What is BPZE1 pertussis vaccine and Boostrix used for?

BPZE1 pertussis vaccine and Boostrix is indicated for Pertussis (whooping cough) prevention in adolescents and adults.

Who makes BPZE1 pertussis vaccine and Boostrix?

BPZE1 pertussis vaccine and Boostrix is developed by ILiAD Biotechnologies (see full ILiAD Biotechnologies pipeline at /company/iliad-biotechnologies).

What drug class is BPZE1 pertussis vaccine and Boostrix in?

BPZE1 pertussis vaccine and Boostrix belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is BPZE1 pertussis vaccine and Boostrix in?

BPZE1 pertussis vaccine and Boostrix is in Phase 2.

What are the side effects of BPZE1 pertussis vaccine and Boostrix?

Common side effects of BPZE1 pertussis vaccine and Boostrix include Local injection site reactions (pain, erythema, swelling), Fever, Myalgia, Headache.

Related